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Abstract
Background: The demographic characteristics of pandemic influenza decedents among middle and low-income
tropical countries are poorly understood. We explored the demographics of persons who died with influenza A
(H1N1)pdm09 infection during 2009–2010, in seven countries in the American tropics.
Methods: We used hospital-based surveillance to identify laboratory-confirmed influenza deaths in Costa Rica, El
Salvador, Guatemala, Honduras, Nicaragua, Panama and Dominican Republic. An influenza death was defined as
a person who died within two weeks of a severe acute respiratory infection (SARI) defined as sudden onset of
fever >38 °C, cough or sore-throat, and shortness of breath, or difficulty breathing requiring hospitalization, and
who tested positive for influenza A (H1N1)pdm09 virus by real time polymerase chain reaction. We abstracted the
demographic and clinical characteristics of the deceased from their medical records.
Results: During May 2009-June 2010, we identified 183 influenza deaths. Their median age was 32 years (IQR 18–46
years). One-hundred and one (55 %) were female of which 20 (20 %) were pregnant and 7 (7 %) were in postpartum.
One-hundred and twelve decedents (61 %) had pre-existing medical conditions, (15 % had obesity, 13 % diabetes,
11 % asthma, 8 % metabolic disorders, 5 % chronic obstructive pulmonary disease, and 10 % neurological disorders).
65 % received oseltamivir but only 5 % received it within 48 h of symptoms onset.
Conclusions: The pandemic killed young adults, pregnant women and those with pre-existing medical conditions.
Most sought care too late to fully benefit from oseltamivir. We recommend countries review antiviral treatment policies
for people at high risk of developing complications.
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Background
Early in the pandemic, the epidemiologic and clinical
characteristics of influenza A (H1N1)pdm09 were poorly
understood. Pending information about this emerging
pathogen, influenza prevention and control policies in
the American tropics still targeted persons at risk of de-
veloping complications as a result of seasonal influenza
disease (e.g. children aged < 5 years, persons with certain
chronic medical conditions, and persons aged ≥ 65 years)
[1]. For example, health officials worried that physiologic
changes during pregnancy and the postpartum period
would place women at risk for developing complications
as a result of pandemic influenza illness [2–4].
At the start of the pandemic, Central American coun-
tries used CDC’s Guidelines for Treatment of Suspected
Cases of Influenza A(H1N1)pdm09 [5]. At the end of
2009, Central America countries sought to implement
the PAHO treatment recommendations developed in
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July 2009 [6]. These recommendations prioritized the early
use of oseltamivir among children, older adults, pregnant
women and people with chronic diseases [7–11]. Health
officials used television, print and radio to urge persons
presumed to be at high-risk who developed sudden onset
fever, cough or sore throat, and all persons who developed
danger signs (e.g. respiratory difficulty), to seek timely care
[7, 12, 13]. Risk communication messages urged the people
to seek medical care, but only Nicaragua, Panamá and
Guatemala, explicitly recommended that to people at high
risk of developing complications from influenza illness
[14–17]. National guidelines recommended to treat pa-
tients with oseltamivir when it was most effective (i.e.
within 48 h from symptom onset) [1, 7, 9, 11, 18, 19].
WHO also recommended to the countries vaccinate
pregnant women and other high risk persons against
pandemic influenza [20]. To accomplish this, WHO pro-
vided three shipments of donated monovalent influenza
A(H1N1)pdm09 vaccine to 4 of the 7 countries in Cen-
tral America during March 2010. This donation was the
only source of influenza vaccine for public health sector
and allowed for a vaccination coverage of 14–34 % among
the general population in Central America (El Salvador:
2,2 million doses, coverage: 34 %; Guatemala: 1,3 million
doses, coverage: 10 %; Honduras: 1,7 million doses, cover-
age: 24 %; Nicaragua: 750,000 doses, coverage: 14 %) [21].
Pharmaceutical interventions in middle and low in-
come countries of the American tropics were in limited
supplies or only available late during the pandemic. In
Central America, while in some countries social security
coverage is almost universal, in others is as low as 12 %.
Investment in health varies between 5-11 % of gross do-
mestic product, the density of beds varies 0.7-2.4 per
1000 inhabitants; physician density 0.4-1.9 per 1000 in-
habitants; and rural population of 25–50 % [22]. In this
manuscript we explore the impact of the pandemic in
Central America and the Dominican Republic through a
description of the demographics, clinical characteristics,




In 2007, the Ministries of Health of Central America
and the Dominican Republic implemented the PAHO-
CDC Generic Protocol for Influenza Surveillance to
identify influenza among severe acute respiratory infec-
tion (SARI) cases (defined as sudden onset fever >38 °C,
cough or sore-throat, and shortness of breath or diffi-
culty breathing requiring hospitalization) [23]. Cases
were tested for influenza through immunofluorescence
and real-time reverse transcription-polymerase chain re-
action. Starting April 2009, countries also documented
laboratory-confirmed influenza A(H1N1)pdm09 SARI
cases that died in hospital within two weeks from illness
onset. We used hospital-based surveillance to identify
laboratory-confirmed influenza deaths in Costa Rica, El
Salvador, Guatemala, Honduras, Nicaragua, Panama and
Dominican Republic. SARI decedents were identified
through event-based surveillance and outbreak response
activities. Upon identifying potential cases, health au-
thorities reviewed clinical records and autopsy reports to
determine if decedents had indeed met the SARI case-
definition.
We defined women of reproductive age as those aged
between 15–49 years. We categorized pregnant women
who developed respiratory illness before delivery as “preg-
nant” and those who developed respiratory illness within
42 days of delivery as “postpartum” cases. We categorized
a case as obese if such a diagnosis was recorded in their
medical record or if height and weight information were
available and the body mass index exceeded 30 kg/m2.
Data collection
We collected data using standardized questionnaires, from
May 2009 to June 2010. Health authorities systematically
obtained demographic (e.g. age and sex) and clinical infor-
mation (e.g. date of illness onset, health seeking behavior,
treatment with oseltamivir, history of pre-existing medical
conditions, symptoms, signs, laboratory, radiology, and
pathology findings) from SARI decedents associated with
influenza A(H1N1)pdm09 from clinical records (by review-
ing the medical records of hospitals, outpatient clinic re-
cords and referral sheets which were available) and
obtaining information from relatives, and surveillance data.
Ethics
The review of the clinical records was performed in the
context of the pandemic outbreak for the characterization
of the first 100 cases, following recommendations of
WHO. For the emergency, at that moment, was no re-
quired approval for IRB. Approvals by Ministries of Health
consisted of administrative permission to access medical
records. The review of medical records was performed
and with the accompaniment of officials of the Ministries
of Health. No patient identifiers were received or used for
analysis.
Analyses
We summarized demographic and clinical characteristics
of decedents associated with influenza A(H1N1)pdm09
using proportions to compare both, as the participation of
each country and as the age groups, with variables of
interest (ie. Percentage of pregnant and postpartum
women, underlying medical conditions and treatment).
We stratified the analyses into three age groups (i.e. 0–18,
19–64 and ≥65 years). We conducted Chi-square, t-tests
and analysis of variance tests for comparisons when
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appropriate. We eliminated missing data from the calcula-
tions, buy declared in the results section.
We verify the check list for observational studies from
the STROBE Statement.
Results
Epidemiologic and demographic case characteristics
During epidemiological week (EW) 19 in 2009 through EW
25 in 2010, we identified 183 SARI decedents who tested
positive for influenza A(H1N1)pdm09 in seven countries
(Belize did not identify any influenza A(H1N1)pdm09
deaths). The first case was identified in Costa Rica during
EW 19. Influenza A(H1N1)pdm09 deaths peaked during
EW 30 (Fig. 1). Forty percent (74 cases) of the 183 dece-
dents were identified in Costa Rica, 17 % (32 cases) in El
Salvador, 11 % (21 cases) in Dominican Republic, 10 % (18
cases) in Honduras, 9 % (17 cases) in Guatemala, 7 % (12
cases) in Panama, and 5 % (9 cases) in Nicaragua (Table 1).
The median age among cases was 32 years (interquar-
tile range: 18–46 years). Children aged <5 years repre-
sented 16 % (29 cases) and persons aged 15–44 years
represented 48 % (88 cases) and persons aged >65 years
represented 9 % (17 cases) of the 183 deaths. El Salvador
had the lowest median age (15 years) and Costa Rica the
highest (41 years) among decedents (Table 1). In El
Salvador, cases aged <5 years were most prevalent (45 %)
while in Guatemala cases aged 35–44 years (35 %).
Seventeen (9 %) of 183 cases had a history of smoking.
Among 112 cases (61 %) with a pre-existing medical
condition, 27 (15 %) were obese, 23 (13 %) had diabetes,
20 (11 %) had asthma, 15 (8 %) had other chronic meta-
bolic diseases, 10 (5 %) had chronic obstructive pulmon-
ary disease, 11 (6 %) had seizure disorder, and 7 (4 %)
had cerebral palsy. Underlying medical conditions were
identified in 38 % of cases <5 years old, in 61 % of cases
aged 5–59 years old, and in all cases with 60 or more
years old (Table 2). Among cases aged <18 years, seizure
disorders (reported among 7 of 46 cases [15 %]) and
asthma (6 cases [13 %]) were the most common pre-
existing medical conditions. Among cases aged 18–64
years, obesity (24 of 120 cases [20 %]) and diabetes mel-
litus (19 cases [16 %]) were the most common. Among
cases aged ≥65 years, diabetes mellitus (4 cases of 17
[24 %]) was the most common pre-existing medical con-
dition. Cases with underlying medical conditions were
older (mean age 37 years) than those without underlying
medical conditions (mean age 26 years) (p < 0.01).
One hundred and one (55 %) of 183 the decedents
were female. Of the 101 female decedents, 61 (60 %)
were women of reproductive age. Thirty-three percent
(20 cases) of women of reproductive age who died were
pregnant, and 7 (12 %) were in their puerperium. El Sal-
vador reported that all women of reproductive age who
died were maternal deaths, Guatemala reported 5 (71 %)
of 7, and Honduras reported 5 (63 %) of 8 were maternal
deaths.
Nearly half (48 %) of the pregnant women were in their
third trimester, 24 % in the second trimester, and 24 % did
not have a gestational age recorded. Fourteen (52 %) of 27
maternal deaths had other underlying medical condition
(i.e. 5 (18 %) had asthma, 3 (11 %) had cardiac disease, 2
[7 %] had obesity, 2 [7 %] had chronic lung disease, 2
[7 %] had diabetes and 1 [4 %] AIDS) (Table 2). The pro-
portion of pre-existing medical conditions between mater-
nal deaths and cases without pregnancy were similar,
except for the proportion with chronic cardiac disease
Fig. 1 Number decedents associated with influenza A(H1N1)pdm09 by epidemiological Week, in Central America, 2009-2010
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which was higher among maternal deaths (11 % [3/27]
cases) when compared to non-pregnant women (3 %
[4/156], p = 0.03). The average age of maternal deaths
was 29 years.
Clinical, laboratory, radiology, and pathology
characteristics
One hundred and fifty-one (82 %) of 183 decedents had
a history of fever before their first contact with a clinic,
but only 85 (46 %) had documented fever during admis-
sion. Dyspnea was reported in only 124 (68 %) of cases
during admission.
Seventy five (41 %) of 183 cases had a chest x-rays
(CXR) during their illness, of which 71 % had consolida-
tion 53 % had interstitial findings. Five (28 %) of the 18
cases with interstitial infiltrates subsequently developed
consolidation during hospitalization. Sixteen (9 %) of the
183 cases had autopsy reports, of which 11 (69 %) had
cardiomegaly, 5 (31 %) intra-alveolar hemorrhage, 4
(25 %) neutrophilic bronchopneumonia, and 4 (25 %)
cerebral edema.
Timing of health seeking and oseltamivir use
Decedents sought care a median of 4 days (IQR 1–5
days) after symptom onset. The median duration be-
tween health seeking and death was 14 days (IQR 6–17
days). There was no statistically significant difference in
the average amount of time elapsed between symptom
onset and health seeking by age groups (p = 0.4), or
country (p = 0.2). Overall, one hundred nineteen (65 %)
out of the 183 cases received treatment with oseltamivir,
(Table 3) but there was variability in the proportion
treated depending on the country where they lived
(range 25–89 %). Of the 119 that received oseltamivir,
only 10 (5 %) received it within the first 48 h of onset of
symptoms, and 21 (11 %) within the first 72 h (Table 3).
Table 1 Demographic characteristics of decedents associated with influenza A(H1N1)pnd09 in Central America, 2009-2010
Country Decedents for influenza H1N1pnd09 General population (2009)








Costa Rica 74 41 (26–55) 4 (5 %) 1.6 % 4.6
Dominican Republic 21 25 (20–36) 5 (24 %) 2.2 % 9.8
El Salvador 32 15 (1–39) 6 (19 %) 2.1 % 6.1
Guatemala 17 34 (24–38) 5 (29 %) 3.3 % 14.0
Honduras 18 26 (3–42) 5 (28 %) 2.7 % 7.4
Nicaragua 9 30 (2–44) 1 (11 %) 2.4 % 5.7
Panama 12 23 (2–51) 1 (8 %) 2.1 % 3.5
All 183 32 (17–46) 27 (15 %) 2.3 % 51.1
The World Bank. Indicators. Birth rate, crude. Data section. Web page. Available in: http://data.worldbank.org/indicator/SP.DYN.CBRT.IN aCalculated using the
annual birth rate for 2009a,b
Table 2 Decedents associated with influenza H1N1pnd09. Pre-existing medical conditions in age risk groups and pregnant and
postpartum women. Central America and Dominican Republic 2009–10
Underlying medical condition All <5 years 5 - 59 years 60+ years Pregnant or postpartum
N = 183 n = 29 n = 134 n = 20 n = 27
Cases % Cases % Cases % Cases % Cases %
Obesity 27 15 % 0 0 % 23 17 % 4 21 % 2 7 %
Diabetes Mellitus 23 13 % 0 0 % 16 12 % 7 37 % 2 7 %
Asthma 20 11 % 2 7 % 15 11 % 3 16 % 5 18 %
Other chronic metabolic disease 15 8 % 1 3 % 9 7 % 5 26 % 0 0 %
Immunosuppression 15 8 % 2 7 % 10 7 % 3 16 % 1 4 %
Chronic lung disease 10 5 % 0 0 % 8 6 % 2 11 % 2 7 %
Chronic seizures 11 6 % 3 10 % 8 6 % 0 0 % 0 0 %
Chronic cardiac disease 7 4 % 1 3 % 5 4 % 1 5 % 3 11 %
Cerebral palsy 7 4 % 1 3 % 6 4 % 0 0 % 0 0 %
At least one chronic condition 112 61 % 11 38 % 82 61 % 19 100 % 14 50 %
Percentages from the total of each category
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Twenty (74 %) of 27 pregnant / postpartum women re-
ceived oseltamivir (4 cases did not receive oseltamivir,
and 4 had no treatment data). Oseltamivir use among
pregnant /postpartum women was significantly higher
compared to women who were not pregnant (OR = 10
[95 % CI 3–32]) but there was no difference between days
from hospitalization and oseltamivir treatment (p = 0.9).
Fifty five percent (100/183 cases) were also tested
through immunofluorescence for other respiratory virus.
Two cases also were positive for respiratory syncytial
virus, 1 for influenza B, 1 for adenovirus, 1 for parainflu-
enza virus. Twenty-three percent (43 cases) were tested
for bacteremia through blood cultures; 1 was positive for
Streptococcus pneumoniae.
Discussion
Decedents infected with influenza A(H1N1)pdm09 were
frequently young, pregnant, or had other pre-existing med-
ical conditions. Unlike seasonal influenza deaths, which
predominately occur among older adults [24, 25], the me-
dian age of those who died with influenza A(H1N1)pdm09
infections was 32 years. More than half had a pre-existing
medical condition. In addition, 15 % of all decedents with
influenza A(H1N1)pdm09 in Central America were re-
ported as maternal deaths, more than twice the 2009
prevalence of pregnancy among study countries (6.5 %)
[26]. The proportion of influenza A(H1N1)pdm09 mater-
nal deaths was more than twice the global estimates (5–
7 %) [27–30]. It could be effect of relevance of maternal
mortality for these countries.
Such findings suggest that the influenza pandemic dis-
proportionately affected pregnant women and mothers
during their puerperium and consider targeting this
group during future epidemic/pandemic periods with
risk communications, early antiviral treatment, and vac-
cination [31].
Costa Rica had the higher proportion of deaths (40 %);
this could be explained by diagnosis skills and access to
health services in this country.
Although most influenza A(H1N1)pdm09 case-patients
were treated with oseltamivir (65 %), less than 6 % re-
ceived oseltamivir within 48 h of symptom onset when the
antiviral are thought to be most effective [32–34]. We
found no evidence that non-pregnant persons at high risk
for complications [5–7, 9, 14, 19, 35] were more likely to
receive timely oseltamivir than other cases. Indeed, there
was a wide variability among the proportion of case-
patients who were treated with oseltamivir depending on
their country of residence. Such findings raise questions
about the accessibility to timely oseltamivir stockpiles,
physicians experience using oseltamivir during routine
clinical care, and direct medical costs associated with osel-
tamivir in the American tropics. Our findings underscore
importance of exploring the timely use of oseltamivir in
middle and low income countries.
This study has important limitations. We assumed that
all SARI decedents identified by health authorities com-
prised the majority of laboratory-confirmed influenza
A(H1N1)pdm09 deaths. It is likely that a proportion of
persons with severe influenza A(H1N1)pdm09 illness
may have remained unidentified or untested and that
these persons could have had different demographic and
clinical characteristics than those identified through sur-
veillance. For example, it is possible that cases with pre-
existing medical conditions may have been preferentially
tested for influenza A(H1N1)pdm09 thus increasing the
proportion of high risk laboratory-confirmed case-patients
identified in our case-series. Also we have no access to so-
cioeconomic status of cases.
Conclusions
Our study demonstrates the utility of influenza surveil-
lance which provided valuable data to the epidemiology
of influenza A(H1N1)pdm09 during 2009–2010. Our
findings suggest that decedents associated with influenza
A(H1N1)pdm09 were frequently young persons with
prevalent pre-existing medical conditions. Our data sug-
gest that few cases received oseltamivir within 48 h of
treatment, highlighting challenges with the use of
Table 3 Treatment of influenza A (H1N1)pnd09 in severe acute respiratory case-patients prior to death in Central America 2009-2010
Treatment All N = 183 Age groups Pregnancy or
postpartum
n = 27
<5 years n = 29 5–59 years n = 133 +60 years n = 21
Cases % Cases % Cases % Cases % Cases %
Acute respiratory distress syndromea 134 73 20 69 97 73 17 81 17 63
Intensive care admissiona 113 62 18 62 84 63 11 52 15 56
Mechanical ventilationa 134 73 21 72 96 72 17 81 15 56
Oseltamivir 119 65 13 45 93 70 13 62 20 74
In first 48 h of symptoms onsetb 10 5 1 8 8 6 1 8 0 0
In first 72 h of symptoms onsetb 21 11 3 23 17 13 1 8 2 7
aPercentage of total category. bPercentage who received oseltamivir
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antivirals during periods of epidemic activity in the re-
gion. Based on these data, current national treatment
protocols urge clinicians prioritize individuals with pre-
existing medical conditions such as pregnancy, asthma,
and diabetes for timely oseltamivir treatment. Future
studies should explore the availability and accessibility of
oseltamivir as well as the potential value for presumptive
treatment of high-risk individuals during periods of epi-
demic influenza activity in tropical middle and low income
countries.
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